Bristol Myers Squibb raised its 2026 sales outlook in July, while Novo Nordisk expects its sales to be flat at best this year, yet Bristol Myers Squibb trades at the lower earnings multiple.
Equillium (NASDAQ:EQ) Chief Scientific Officer Stephen Connelly outlined the company’s plans to advance its lead programs, including an oral aryl hydrocarbon receptor, or AhR, modulator for ulcerative colitis and an oral bispecific peptide for celiac disease, during a fireside chat.
Connelly said t
AI's power bottleneck is creating two very different opportunities. See how GE Vernova and Bloom Energy compare in terms of growth, valuation, risk, and ability to power the data center boom.
Columbus McKinnon (NASDAQ:CMCO) CFO John Linker said the company is focused on executing its integration of Kito Crosby, delivering planned cost synergies and reducing debt following the transformative acquisition.
Linker, who joined the company July 1, told Sidoti conference attendees that the Kit
Tamboran Resources (NYSE:TBN) said it has begun selling gas from the Beetaloo Basin into the Northern Territory market, marking a milestone for the company as it works to establish longer-term production performance and advance broader development plans.
Chief Executive Officer Todd Abbott said gas
ThredUp (NASDAQ:TDUP) executives said the online resale company delivered a record second quarter across buyers, sellers, orders and revenue, while also navigating a recent shift toward more price-sensitive behavior among budget-conscious consumers.
Speaking at Wells Fargo’s consumer conference, Ch
Palantir's growth is extraordinary, but the valuation sets a demanding bar. See what AIP, margins, government demand, and the math reveal about its long-term upside.
Nkarta (NASDAQ:NKTX) said it expects to present initial clinical data from its autoimmune disease programs at the American College of Rheumatology’s 2026 Convergence meeting in November, including presentations in myositis, scleroderma and program-wide safety.
The company is developing an allogenei
A wave of AI leaders are warning about the pace of frontier models and their fear of them getting “out of control.” However, there may be other reasons why they’re sounding the alarm at this precise moment.
PRA Group (NASDAQ:PRAA) outlined its strategy, operating trends and capital priorities during a company presentation, highlighting a favorable supply environment for non-performing loan portfolios, ongoing cost reductions and investments in technology.
Chief Executive Officer Martin Sjolund said th
Palisade Bio (NASDAQ:PALI) said it is advancing its lead drug candidate, PALI-2108, into Phase II studies for ulcerative colitis and Crohn’s disease after completing its Phase I program.
Chief Executive Officer JD Finley said PALI-2108 is a once-daily oral phosphodiesterase 4, or PDE4, inhibitor de
Every year, NFL teams spend months studying the next class of potential stars. My colleague Louis Navellier sees a similar dynamic unfolding in the stock market today. After years of mega-cap dominance, smaller companies are beginning to take the lead—but that doesn’t mean every small-cap stock deserves a place in your portfolio.
One of the most challenging decisions to make as you near retirement is when to claim Social Security benefits. Here are five reasons 65 might be the sweet spot.
Strong leasing demand and limited new supply are boosting top-tier office REITs like SL Green, BXP and Hudson Pacific, which trade far cheaper than data-center REITs Equinix and Digital Realty.
Xenon Pharmaceuticals (NASDAQ:XENE) said it has filed its first new drug application for azetukalner as a treatment for focal-onset seizures, while pausing portions of its late-stage psychiatry program to evaluate changes intended to improve tolerability.
Speaking at the 2026 TD Cowen Neuropsychiat
